Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Zeller, T; Beschorner, U; Pilger, E; Bosiers, M; Deloose, K; Peeters, P; Scheinert, D; Schulte, KL; Rastan, A; Brodmann, M.
Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).
JACC Cardiovasc Interv. 2015; 8(12):1614-1622 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Brodmann Marianne
Pilger Ernst

Dimensions Citations:

Plum Analytics:
The aim of BIOLUX P-II (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries) trial was to compare the safety and efficacy of a novel paclitaxel-coated drug-eluting balloon (DEB) versus an uncoated balloon (percutaneous transluminal angioplasty [PTA]) in de novo or native restenotic lesions of the infrapopliteal arteries in patients with claudication and critical limb ischemia. DEB have shown promising results in femoropopliteal lesions, but data for infrapopliteal lesions are scarce. In this prospective, multicenter, randomized first-in-man study, 72 patients were randomized 1:1 to either a Passeo-18 Lux DEB (Biotronik AG, Buelach, Switzerland) (n = 36) or Passeo-18 PTA (n = 36). Follow-up assessments were scheduled at 1, 6, and 12 months, with angiographic assessment at 6 months. Adverse events were adjudicated by an independent clinical events committee, and angiographic parameters were assessed by an independent core laboratory. The primary safety endpoint (a composite of all-cause mortality, target extremity major amputation, target lesion thrombosis, and target vessel revascularization at 30 days) was 0% in the DEB group versus 8.3% in the PTA group (p = 0.239). The primary performance endpoint (patency loss at 6 months) was 17.1% in the DEB group versus 26.1% in the PTA group (p = 0.298), and major amputations of the target extremity occurred in 3.3% versus 5.6% of the patients at 12 months, respectively. The Passeo-18 Lux DEB has been proven to be safe and effective in infrapopliteal lesions with comparable outcomes to PTA. Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Aged -
Aged, 80 and over -
Amputation -
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - instrumentation
Angioplasty, Balloon - mortality
Cardiovascular Agents - administration & dosage
Coated Materials, Biocompatible -
Critical Illness -
Equipment Design -
Female -
Humans -
Intermittent Claudication - diagnosis
Intermittent Claudication - mortality
Intermittent Claudication - physiopathology
Intermittent Claudication - therapy
Ischemia - diagnosis
Ischemia - mortality
Ischemia - physiopathology
Ischemia - therapy
Limb Salvage -
Male -
Middle Aged -
Paclitaxel - administration & dosage
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - mortality
Peripheral Arterial Disease - physiopathology
Peripheral Arterial Disease - therapy
Popliteal Artery - diagnostic imaging
Popliteal Artery - physiopathology
Prospective Studies -
Radiography -
Recurrence -
Time Factors -
Treatment Outcome -
Vascular Access Devices -
Vascular Patency -
Young Adult -

Find related publications in this database (Keywords)
critical limb ischemia
drug-coated balloon
drug-eluting balloon
peripheral artery disease
© Meduni Graz Impressum